Company profile
UK company NI667396, incorporated on 31 January 2020.
Home - GenoME Diagnostics - Diagnosis-of-ovarian-cancer
GenoME Diagnostics - We are developing a blood test for an earlier and more accurate diagnosis of ovarian cancer.GenoME Diagnostics .
Company number NI667396
Updated 07 Jul 2026 09:49
Financial period: 1 Feb 2024 to 31 Jan 2025
Reference milestones and recent Companies House filing stream events.
AA | Transaction MzU0ODQ3NDY2OGFkaXF6a2N4
Published 30 Sep 2026 09:55
Company registered at Companies House
GenoME Diagnostics develops blood tests to detect signs of ovarian cancer earlier than conventional methods.
This company develops technology for a DNA-methylation based cancer biomarker panels, with a first product being for applications in Ovarian Cancer diagnostics
The company founders won £50K of funding from Innovate UK's ICURe programme for customer discovery and team formation, and then successfully applied for £300K of support from the Innovate UK aid for start-ups scheme. GenoMe Diagnostics were awarded the "best new start on the island of Ireland" prize at the Intertrade Ireland seedcorn competition in 2020, winning an additional 20K Euro
1 Apr 2026 to 31 Mar 2027
\>460,000 people/year are diagnosed with pancreatic cancer (PC) globally. Unfortunately, due to non-specific symptoms which often present late, and the current sub-optimal diagnostic tests for PC, it is often only diagnosed in the later stages, and usually when it has already spread to secondary locations. The survival statistics are alarming, \>75% of pa...
1 Jul 2025 to 30 Jun 2026
Over 300,000 people/year are diagnosed with ovarian cancer (OC) globally. Unfortunately, the diagnosis and treatment of OC has been very problematic. OC is often diagnosed in late stages due to non-specific symptoms and sub-optimal diagnostics. Once diagnosed, 70% patients will then relapse within 2 years, with only 35% patients surviving for 5 years. Oft...
1 May 2024 to 30 Apr 2025
Ovarian Cancer is notoriously difficult to diagnose, with the majority of diagnoses achieved only in the later stages of the disease. The current blood marker, CA125, is not fit for purpose as it cannot detect up to 50% of early stage Ovarian Cancers, and its levels are not elevated in up to 20% of confirmed late stage Ovarian Cancers. Whilst CA125 is con...
1 Dec 2022 to 30 Nov 2025
Almost 460,000 people a year are diagnosed with pancreatic cancer across the world, with the number of cases predicted to rise by 6% over the coming decades due to a plateau in research developments and therapeutic advancements. Unfortunately, due to non-specific symptoms which often present late, and the current sub-optimal diagnostic tests for pancreati...
1 Apr 2022 to 31 Mar 2023
Almost 300,000 women a year are diagnosed with ovarian cancer across the world. The number of cases is predicted to rise by 15% in the coming years. Unfortunately, due to non-specific symptoms and the current sub-optimal diagnostic testing for ovarian cancer, it is often only diagnosed in the later stages of disease when it has already spread. In the UK m...
1 Mar 2021 to 30 Sep 2022
Almost 300,000 women a year are diagnosed with Ovarian cancer across the world, with the number of cases are predicted to rise by 15% over the coming decades due to a plateau in research developments and therapeutic advancements. Unfortunately, due to non-specific symptoms of this disease and the sub-optimal diagnostic test for Ovarian cancer, it is often...
